Medical Imaging (MEDD) 10-Q 2015 Q3 Quarterly report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2015

¨ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

for the transition period from _________________ to _______________

Commission File Number 333-136436

MEDICAL IMAGING CORP.

(Exact name of registrant as specified in charter)

NEVADA	98-0493698
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

848 N. Rainbow Blvd. #2494, Las Vegas, Nevada	89107
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code   (877) 331-3444

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ý No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes ý No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer    o	Accelerated filer    o
Non-accelerated filer    o (Do not check if smaller reporting company)	Smaller reporting company    ý

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes o No ý

As of November 9, 2015 the Company had outstanding 24,166,481 shares of its common stock.

TABLE OF CONTENTS

ITEM NUMBER AND CAPTION	PAGE
PART I
ITEM 1.      Consolidated Financial Statements and Supplementary Data (Unaudited)	3
ITEM 2.      Management’s Discussion and Analysis of Financial Condition And Results of Operations	20
ITEM 3       Quantitative and Qualitative Disclosures About Market Risk Controls and Procedures	25
ITEM 4T     Controls and Procedures	25
PART II
ITEM 1.       Legal Proceedings	26
ITEM 1A.    Risk Factors	26
ITEM 2.       Unregistered Sales of Equity Securities and Use of Proceeds	26
ITEM 3.       Defaults Upon Senior Securities	27
ITEM 4.       Mine Safety Disclosures	27
ITEM 5.       Other Information	27
ITEM 6.       Exhibits	27

2

Item 1. Consolidated Financial Statements

Medical Imaging Corp.

Consolidated Balance Sheets (Unaudited)

	September 30,		December 31,
	2015		2014
ASSETS
Current Assets
Cash and Cash Equivalents	$	159,948	$	188,206
Accounts Receivable, net		1,235,374		851,884
Prepaid Expenses		46,905		24,165
Total Current Assets		1,442,227		1,064,255
Property and Equipment
Equipment		3,458,377		3,402,671
Less: Accumulated Depreciation		(864,694)		(463,977)
Total Property and Equipment, net		2,593,683		2,938,694
Goodwill		1,977,670		1,977,670
Other Assets
Deposits		11,884		12,463
Loan Receivable		-		1,497
Total Other Assets		11,884		13,960
TOTAL ASSETS	$	6,025,464	$	5,994,579
LIABILITIES AND STOCKHOLDERS'  DEFICIT
Current Liabilities
Accounts Payable	$	1,069,240	$	624,141
Accrued Liabilities		464,163		311,547
Obligations Under Capital Lease, short term portion		212,427		189,923
Promissory Notes, short term portion		427,944		134,999
Royalty Financing, short term portion		102,474		102,219
Convertible Notes, net short term portion		567,055		54,263
Total Current Liabilities		2,843,303		1,417,092
Long Term Liabilities
Obligations Under Capital Lease, long term portion		323,366		459,853
Royalty Financing, long term portion		1,858,204		1,902,698
Convertible Notes, net long term portion		1,865,092		2,332,708
Total Long Term Liabilities		4,046,662		4,695,259
Total Liabilities		6,889,965		6,112,351
Stockholders' Deficit
Preferred Stock-$0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively		-		-
Common Stock-$0.001 par value; 500,000,000 shares authorized, 24,166,481 and 23,946,481 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively		24,167		23,947
Additional Paid-In Capital		1,970,223		1,876,484
Accumulated Other Comprehensive Gain		107,077		21,393
Accumulated Deficit		(2,965,968)		(2,039,596)
Total Stockholders' Deficit		(864,501)		(117,772)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	6,025,464	$	5,994,579

The accompanying notes are an integral part of these consolidated financial statements.

3

Medical Imaging Corp.

Consolidated Statements of Operations (Unaudited)

	Three Months Ending				Nine Months Ending
	September 30		September 30		September 30		September 30
	2015		2014		2015		2014
Revenue:
Sales	$	1,675,399	$	1,275,341	$	5,500,217	$	3,787,403
Less: Cost of Sales		937,795		711,346		2,865,499		2,212,967
Gross Margin		737,604		563,995		2,634,718		1,574,436
Operating Expenses:
Labor		318,167		221,148		957,660		597,412
General and Administrative		172,640		94,332		525,065		202,829
Depreciation		137,116		50,252		409,854		129,907
Rent Office Space and Servers		128,211		39,534		393,663		113,256
Legal and Professional		82,985		40,322		305,180		138,400
Insurance		20,766		10,724		69,928		33,832
Travel		10,091		4,697		31,202		31,167
Advertising		5,833		8,290		23,415		42,543
Management Fees		5,100		4,778		28,513		13,866
Amortization		-		-		-		22,925
Bad Debt Expense (Recapture)		(849)		(515)		5,530		14,465
Total Operating Expenses		880,060		473,562		2,750,010		1,340,602
Income (Loss)from Operations		(142,456)		90,433		(115,292)		233,834
Other Income and (Expenses):
Other Income		7,326		512		15,971		715
Foreign Currency Gains (Losses)		14,046		145		(3,473)		954
Interest, Discount of Debt & Penalties Expenses		(404,435)		(112,323)		(867,542)		(306,011)
Total Other Income (Expenses)		(383,063)		(111,666)		(855,044)		(304,342)
Loss Before Provision for Income Taxes		(525,519)		(21,233)		(970,336)		(70,508)
Provision for Income (Taxes) Credit		(1,092)		5,122		43,964		5,122
Net Loss		(526,611)		(16,111)		(926,372)		(65,386)
Comprehensive Income		28,633		334		85,684		63
Total Comprehensive Loss	$	(497,978)	$	(15,777)	$	(840,688)	$	(65,323)
Basic and Diluted Loss per Share	$	(0.021)	$	(0.001)	$	(0.035)	$	(0.003)
Weighted Average Shares Outstanding:
Basic and Diluted		24,166,481		23,850,828		24,143,183		23,688,366

The accompanying notes are an integral part of these consolidated financial statements.

4

Medical Imaging Corp.

Consolidated Statements of Cash Flows (Unaudited)

	Nine Months Ended
	September 30		September 30
	2015		2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$	(926,372)	$	(65,386)
Adjustments to Reconcile Net Loss to Net Cash provided by Operating Activities:
Depreciation		409,854		129,907
Asset Write Off		-		961
Accrued Interest Converted Into Note		-		209,078
Amortization of Debt Discount		463,383		66,283
Stock-Based Compensation		92,919		150
Amortization of Intangible Assets		-		22,925
Foreign Currency Transaction Loss		579		498
Changes in Operating Assets and Liabilities:
Accounts Receivable		(383,490)		(148,193)
Prepaid Expenses		(22,740)		(29,131)
Loan Receivable		1,497		260
Accounts Payable and accrued liabilities		597,715		115,400
NET CASH AND CASH EQUIVALENTS PROVIDED BY OPERATING ACTIVITIES		233,345		302,752
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments on acquisition liability		-		(110,063)
Deposit on Possible Acquisition		-		(20,000)
Equipment Purchase		(45,633)		(372,719)
NET CASH  USED IN  INVESTING ACTIVITIES		(45,633)		(502,782)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from Promissory Notes		1,171,137		-
Proceeds from Convertible Debt		20,000		445,000
Royalty Fee Payment		(310,348)
Principal Payment on Convertible Debt		(45,000)		230,255
Principal Payments on Promissory Notes		(1,004,420)		(26,483)
Principal Payments on Capital Lease Obligations		(133,023)		8,720
NET CASH AND CASH EQUIVALENTS PROVIDE D BY (USED IN) FINANCING ACTIVITIES		(301,654)		196,982
Gain (Loss) due to foreign currency translation		85,684		63
NET CHANGE IN CASH AND CASH EQUIVALENTS		(28,258)		(2,985)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD		188,206		77,300
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	159,948	$	74,315
Cash paid during the year for:
Interest	$	261,838	$	30,650
Income Taxes	$	29,295	$	54,864
Non-cash financing and investing activities:
Shares Issued for Convertible Note	$	1,040	$	37,155
Acquisition Liability Assigned to Loan Payable	$	-	$	64,937
Acquisition Liability Assigned to Promissory Note	$	-	$	25,000
Equipment purchased under Capital Lease	$	18,997	$	-
Accrued Interest converted to Note	$	75,039	$	-

The accompanying notes are an integral part of these consolidated financial statements.

5

Medical Imaging Corp.

Notes to Consolidated Financial Statements (Unaudited)

September 30, 2015

Note 1.  Organization and Summary of Significant Accounting Policies

Organization and Basis of Presentation

Medical Imaging Corp., (“MIC” or the “Company”), formerly: Diagnostic Imaging International Corp. (“DIIC”) a Nevada Corporation was incorporated in 2000. In 2005, the Company developed a business plan for private healthcare opportunities in Canada with the objective of owning and operating private diagnostic imaging clinics. In 2009, the Company purchased Canadian Teleradiology Services Inc., which operates as: Custom Teleradiology Services (“CTS”), CTS provides remote reading of medical diagnostic imaging scans for rural hospitals and clinics. In early 2010, the Company modified its business plan to grow its CTS subsidiary while commencing the acquisition of existing full service imaging clinics located in the United States and exploring the development of new diagnostic imaging technology. In 2012, the Company purchased Schuylkill Open MRI Inc., which operates as: Schuylkill Medical Imaging (“SMI”) an independent diagnostic imaging facility located in Pottsville, Pennsylvania. In 2014, the company purchased Partners Imaging Center of Venice, LLC (“PIV”) located in Venice, Florida; Partners Imaging Center of Naples, LLC (“PIN”) located in Naples, Florida; and Partners Imaging Center of Charlotte, LLC (“PIC”) located in Port Charlotte, Florida.

Basis of Presentation

These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year-end is December 31.

Principle of Consolidation

The consolidated financial statements include the accounts of Medical Imaging, Corp., and our wholly-owned subsidiaries, CTS, SMI, PIV, PIN, and PIC. Intercompany accounts and transactions have been eliminated in the consolidated financial statements. CTS’, SMI’s, PIV’s, PIN’s, and PIC’s accumulated earnings prior to their acquisitions (March 2, 2009, December 10, 2012, and November 1, 2014, respectively) are not included in the consolidated balance sheet.

Use of Estimates and Assumptions

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States (“GAAP”) requires management to make estimates and assumptions that affect (i) the reported amounts of assets and liabilities, (ii) the disclosure of contingent assets and liabilities known to exist as of the date the consolidated financial statements are published, and (iii) the reported amount of net sales, expenses and costs recognized during the periods presented. Adjustments made with respect to the use of estimates often relate to improved information not previously available. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of consolidated financial statements; accordingly, actual results could differ from these estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  At September 30, 2015, and December 31, 2014, cash includes cash on hand and cash in the bank.

Accounts Receivable Credit Risk

The allowance for doubtful accounts is maintained at a level sufficient to provide for estimated credit losses based on evaluating known and inherent risks in the receivables portfolio.

Management evaluates various factors including expected losses and economic conditions to predict the estimated realization on outstanding receivables. As of September 30, 2015 and December 31, 2014, the allowance for bad debts was $70,203 and $64,673, respectively.

Bad debt recapture for the three months ended September 30, 2015 and 2014 was $849 and $515, respectively.

Bad debt expense for the nine months ended September 30, 2015 and 2014 was $5,530 and $14,465, respectively.

6

As of September 30, 2015 two customers of CTS totalled approximately 9% of the total accounts receivable. As of December 31, 2014, three customers totalled approximately 16% of the total accounts receivable.

Goodwill and Indefinite Intangible Assets

The Company follows the provisions of Financial Accounting Standard (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, Goodwill and Other Intangible Assets. In accordance with ASC Topic 350, goodwill, representing the excess of the purchase price and related costs over the value assigned to net tangible and identifiable intangible assets of businesses acquired and accounted for under the purchase method, acquired in business combinations is assigned to reporting units that are expected to benefit from the synergies of the combination as of the acquisitions date. Under this standard, goodwill and intangibles with indefinite useful lives are not amortized.  The Company assesses goodwill and indefinite-lived intangible assets for impairment annually during the fourth quarter, or more frequently if events and circumstances indicate impairment may have occurred in accordance with ASC Topic 350. If the carrying value of a reporting unit's goodwill exceeds its implied fair value, the Company records an impairment loss equal to the difference. ASC Topic 350 also requires that the fair value of indefinite-lived purchased intangible assets be estimated and compared to the carrying value. The Company recognizes an impairment loss when the estimated fair value of the indefinite-lived purchased intangible assets is less than the carrying value. As of September 30, 2015, the Company has goodwill of $1,977,670.  Of the total amount, $1,422,670 is as result of the acquisition of SMI on December 10, 2012, and $132,143, $158,571, and $264,286 as a result of the acquisitions of PIC, PIN, PIV, respectively, which occurred on October 31, 2014. If the implied fair value of goodwill is lower than its carrying amount, goodwill impairment is indicated and goodwill is written down to its implied fair value. Subsequent increases in goodwill value are not recognized in the consolidated financial statements.

Revenue Recognition

The Company holds contracts with several hospitals and groups of health care facilities to provide Teleradiology services for a specific period of time. The Company bills for services rendered on a monthly basis.  For the nine months ended September 30, 2015, CTS held six contracts; four contracts that are renewable on a year-to-year basis, two contracts that are renewable in 2016, and 2018. As described above, in accordance with the requirement of Staff Accounting Bulletin (“SAB”) 104, the Company recognizes revenue when: (1) persuasive evidence of an arrangement exists (contracts); (2) delivery has occurred (monthly); (3) the seller’s price is fixed or determinable (per the customer’s contract, and services performed); and (4) collectability is reasonably assured (based upon our credit policy).

Revenue is accounted for under the guidelines established by SAB 101, Revenue Recognition in Financial Statements, and ASC Topic 605-45, Revenue Recognition – Principal Agent Considerations. For CTS, the Company has the following indicators of gross revenue reporting: (1) CTS is the primary obligator in the provision of services to the Hospitals under contract, (2) CTS has latitude in establishing price, and negotiating contracts with each hospital, (3) CTS negotiates and determines the service specification to be provided to each hospital client, (4) CTS has complete discretion in supplier selection, and (5) CTS has the credit risk. Accordingly, the Company records CTS revenue at gross.

For SMI, PIV, PIN, and PIC revenue is recognized on the date of service, and recorded on an aggregate monthly basis.

Cost of Sales

Cost of sales includes fees paid to radiologists for reading services, transcription fees, equipment repairs, system license and usage costs.

Impairment of Long-Lived Assets

In accordance with ASC Topic 360, Property, Plant and Equipment, property, plant, and equipment, and purchased intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Goodwill and other intangible assets are tested for impairment at least annually.  Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset.

7

Amortization and Depreciation

Depreciation and amortization are calculated using the straight-line method over the following useful lives:

3 - 7 years

Equipment

5 – 7 years

Furniture and Fixtures

3 - 5 years

Non-compete Contract

39 years

Leasehold Improvements

Stock Based Compensation

The Company follows ASC 718, stock compensation; a fair calculation is performed by the Company to establish the “grant date fair value” of each award which will also be the amount recorded by the Company as stock based compensation expense pursuant to the guidance set forth in ASC 718 to produce an estimated fair value.

The Company measures all share-based payments to employees (which includes non-employee Board of Directors), including employee stock options, warrants and restricted stock, at the fair value of the award and expenses it over the requisite service period (generally the vesting period). The fair value of common stock options or warrants granted to employees is estimated at the date of grant using the binomial option pricing model (“BOPM”). The calculation also takes into account the common stock fair market value at the grant date, the exercise price, the expected life of the common stock option or warrant, the dividend yield and the risk-free interest rate.

The Company from time to time may issue stock options, warrants and restricted stock to acquire goods or services from third parties. Restricted stock, options or warrants issued to other than employees or directors are recorded on the basis of their fair value. The options or warrants are valued using the BOPM on the basis of the market price of the underlying equity instrument on the “valuation date,” which for options and warrants related to contracts that have substantial disincentives to non-performance, is the date of the contract, and for all other contracts is the vesting date. Expenses related to the options and warrants are recognized on a straight-line basis over the period which services are to be received.

The Company did not recognized stock-based compensation expenses from stock options to non-employees for the three months ended September 30, 2015 and 2014.

The Company recognized stock-based compensation expenses of $34,683 and $0 from stock options granted to non-employees for the nine months ended September 30, 2015 and 2014.

The stock based compensation for the nine months ended September 30, 2015 pertains to stock options granted to non-employees. The options were valued using the BOPM and included in the Legal and professional operating expenses in the consolidated statements of operations.

The Company recognized stock-based compensation expenses of $0 from stock and stock options granted to employees for the three months ended September 30, 2015, and 2014, respectively.

The Company recognized stock-based compensation expenses of $58,236, and $150 from stock and stock options granted to employees for the nine months ended September 30, 2015, and 2014, respectively.

The stock based compensation for the nine months ended September 30, 2015 includes stock options granted to employees of $47,896.

The options were valued using the BOPM and included in the labor and management fees operating expenses in the consolidated statements of operations for $34,683, and $13,213, respectively.

Fair Value of Financial Instruments

The fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties other than in a forced sale or liquidation.

The carrying amounts of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses, accounts payable, accrued liabilities and notes and loans payable approximate fair value due to their most maturities.

8

Fair Value Measurements

The Company follows paragraph 825-10-50-10 of the FASB Accounting Standards Codification (“ASC”) for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB ASC (“Paragraph 820-10-35-37”) to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value in U.S. GAAP, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, Paragraph 820-10-35-37 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by Paragraph 820-10-35-37 are described below:

Level 1

Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.

Level 2

Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.

Level 3

Pricing inputs that are generally observable inputs and not corroborated by market data.

The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values because of the short maturity of these instruments.

The company does not have assets and liabilities that are carried at fair value on a recurring basis.

Foreign Currency Translation

The Company’s functional currency for its wholly-owned subsidiary, CTS, is the Canadian dollar, and their financial statements have been translated into U.S. dollars. The Canadian dollar based accounts of the Company’s foreign operations have been translated into United States dollars using the current rate method. Assets and liabilities of those operations are translated into U.S. dollars using exchange rates as of the balance sheet date; income and expenses are translated using the weighted average exchange rates for the reporting period. Translation adjustments are recorded as accumulated other comprehensive income (loss), a separate component of stockholders’ equity.

The Company recognized a foreign currency gain on transactions from operations of $14,046 and foreign currency gain of $145 for the three months ended September 30, 2015 and 2014, respectively.

The Company recognized a foreign currency loss on transactions from operations of $3,473 and foreign currency gain of $954 for the nine months ended September 30, 2015 and 2014, respectively.

The Company recognized total comprehensive income of $28,633 and $334 for the three months ended September 30, 2015 and 2014, respectively.

The Company recognized total comprehensive income of $85,684 and $63 for the nine months ended September 30, 2015 and 2014, respectively.

Income Taxes

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes.  This statement prescribes the use of the asset and liability method whereby deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.

Net Income (Loss) Per Share

The Company follows the provisions of ASC Topic 260, Earnings per Share.  Basic net income (loss) per share is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Basic and diluted losses per share are the same as all potentially dilutive securities are anti-dilutive.

9

Basic earnings per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if stock options and other commitments to issue common stock were exercised or equity awards vest resulting in the issuance of common stock or conversion of notes into shares of the Company’s common stock that could increase the number of shares outstanding and lower the earnings per share of the Company’s common stock. This calculation is not done for periods in a loss position as this would be antidilutive.

The information related to basic and diluted earnings per share is as follows:

	Three Months Ended				Nine Months Ended
	September 30, 2015		September 30, 2014		September 30, 2015		September 30, 2014
Numerator:
Continuing operations:
Total Comprehensive Loss	$	(497,978)	$	(15,777)	$	(840,688)	$	(65,323)
Total	$	(497,978)	$	(15,777)	$	(840,688)	$	(65,323)
Total Comprehensive Loss	$	(497,978)	$	(15,777)	$	(840,688)	$	(65,323)
Denominator:
Weighted average number of shares outstanding – basic and diluted		24,166,481		23,850,828		24,143,183		23,688,366
EPS:
Basic:
Total Comprehensive Loss	$	(0.021)	$	(0.001)	$	(0.035)	$	(0.003)
Net Loss	$	(0.021)	$	(0.001)	$	(0.035)	$	(0.003)
Diluted
Total Comprehensive Loss	$	(0.021)	$	(0.001)	$	(0.035)	$	(0.003)
Total Comprehensive Loss	$	(0.021)	$	(0.001)	$	(0.035)	$	(0.003)

Recent Accounting Updates

The Company does not expect the adoption of any other recently issued accounting pronouncements to have a significant impact on its results of operations, financial position or cash flow.

Note 2. Interim Financial Statements

The accompanying interim unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine month period ended September 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. For further information, refer to the financial statements and footnotes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014.

Note 3. Property and Equipment

For the nine months ended, September 30, 2015, the Company has acquired additional computer equipment of $30,834 for its CTS subsidiary and additional medical imaging equipment hardware of $33,796 for its PIV subsidiary.

Property and equipment are stated at cost.  Depreciation is calculated using the straight - line method over the estimated useful life of the assets. At September 30, 2015 and December 31, 2014, the major class of property and equipment were as follows:

	September 30, 2015		December 31, 2014		Estimated useful lives
Computer/Office Equipment	$	457,776	$	435,867	3-7 years
Medical Equipment		2,156,820		2,123,023	3-7 years
Leasehold Improvements		843,781		843,781	39 years
Less: Accumulated Depreciation		(864,694)		(463,977)
Net Book Value	$	2,593,683	$	2,938,694

10

Depreciation expense was $137,116 and $50,252 for the three months ended September 30, 2015 and 2014, respectively.

Depreciation expense was $409,854 and $129,907 for the nine months ended September 30, 2015 and 2014, respectively.

Note 4. Business Combination

On October 31, 2014, the Company acquired 100% of the shares of three separate entities, Partners Imaging Center of Venice, LLC, Partners Imaging Center of Naples, LLC, and Partners Imaging Center of Charlotte, LLC., for an aggregate cash consideration described in detail below.  Each company was purchased for its medical equipment, general office fixtures, Medicare number and facility lease.  There were no prior earnings, accounts receivable, accounts payable, or other assets or liabilities acquired in any of the acquisitions. Medical imaging services began to be offered on November 1, 2014 by PIV, PIN, and PIC.

The Company paid an aggregate purchase price of $1,800,000 as follows (at fair value):

	Total		PIV	PIN	PIC
Cash	$	1,800,000	959,286	533,571	307,143
Total consideration paid	$	1,800,000	959,286	533,571	307,143

The following assets and liabilities were recognized (at fair value):

	Total		PIV	PIN	PIC
Fixed Assets	$	1,245,000	695,000	375,000	175,000
Goodwill		555,000	264,286	158,571	132,143
Net assets purchased	$	1,800,000	959,286	533,571	307,143

The Company has evaluated the transactions and believes that the historical cost of the tangible and intangible assets acquired approximated the fair market value given the current nature of the assets acquired.  As part of the acquisitions, the Company has acquired aggregate Goodwill of $555,000. The Company expects to amortize the full amounts of goodwill for tax purposes. The Company will perform annual testing of goodwill for impairment.

The amounts of revenue and gross earnings included in the consolidated income statement for the nine months ended September 30, 2015 and 2014 are as follow:

Nine Months Ended September 30, 2015	Total		PIV	PIN	PIC
Revenue	$	2,282,359	1,064,262	555,754	662,343
Gross Margin	$	1,329,854	591,889	328,564	409,401

Nine Months Ended September 30, 2014	Total		PIV	PIN	PIC
Revenue	$	-	-	-	-
Gross Margin	$	-	-	-	-

Costs related to the acquisitions, which include legal fees, in the aggregate amount of about $29,500 have been charged directly to operations and are included in legal and professional expenses in the 2014 consolidated income statement.

Note 5. Goodwill

The change in the carrying amount of goodwill for the two years ended September 30, 2015 was:

Balance as of January 1, 2014	$	1,422,670
Acquisition of goodwill during the year		555,000
Changes in goodwill during the year		-
Balance as of December 31, 2014		1,977,670
Changes in goodwill during the year		-
Balance as of September 30, 2015	$	1,977,670

11

Note 6.  Lease Commitments

CTS has a lease commitment for its office space of approximately $2,450 minimum rental, and approximately $3,550 in utilities, realty taxes, and operating costs, for a total of approximately $6,000 per month. The Lease renewed in April 2013 for a period of five years and will expire in March 2018. On renewal, CTS was given a rental credit of approximately $28,000. This lease was accounted for as an operating lease.

SMI entered into a lease commitment for its office space in Pottsville, Pennsylvania. The lease will expire on June 30, 2016, and it is renewable for an additional term of 5 years on the same terms and conditions. Monthly rental amounts in 2014 were $5,437 per month plus approximately $1,674 in utilities, realty taxes, and operating costs.

SMI has a lease for office space in Dallas, Texas of approximately $880 per month. The lease will expire in August 31, 2016.

PIV has a lease for office space in Venice, Florida. The lease will expire October 1, 2016. Monthly rental amounts are $15,377 per month.

PIN has a lease for office space in Naples, Florida. The lease will expire January 1, 2020. Monthly rental amounts are $9,543 per month.

PIC has a lease for office space in Port Charlotte, Florida. The lease will expire June 20, 2016. Monthly rental amounts are $5,512 per month.

Expected Lease commitments for the next three years:

Year	Office Space		Servers		Total
2015	$	133,269	$	4,500	$	137,769
2016		423,943		18,000		441,943
2017		186,516		6,000		192,516
	$	743,727	$	28,500	$	772,227

Note 7. Accounts Payable and Accrued Liabilities

As of September 30, 2015 and December 31, 2014, the trade payables and accrued liabilities of the Company were $1,533,403 and $935,688, respectively.

Of the total amount as of September 30, 2015, $1,069,240 was related to ongoing operations representing a balance owing to trade payables. $288,502 was related to accrued payroll and withholdings liabilities, and $175,661 was related to Federal and State income tax owing.

Of the total amount as of December 31, 2014, $624,141 was related to ongoing operations representing a balance owing to trade payables. $73,461 was related to accrued payroll and withholdings liabilities, and $238,086 was related to Federal and State income tax owing.

Note 8. Obligations Under Capital Lease

SMI MRI Machines Capital Lease:

On December 10, 2012, the Company entered into a lease agreement with one of the sellers of SMI to lease the two MRI machines. Under the terms of the lease, SMI is to make monthly payments of $11,013, plus applicable sales tax, over a period of 48 months.  In addition, SMI agreed to make a one-time lease payment of $125,000, which was paid by March 30, 2013. The Company has guaranteed all of SMI’s obligations under the lease.  At the end of the lease, SMI will have the option to purchase the MRI machines for a total purchase price of $1.00. The lease was accounted for as a capital lease for a total value of $555,000.

The gross amount of the equipment held under capital leases totals $555,000 ($240,583 net book value after accumulated amortization of $314,417) at September 30, 2015.

Amortization of the capital lease assets is included in the depreciation expense of $27,750 for the three months ended September 30, 2015 and 2014, respectively.  Amortization of the capital lease assets is included in the depreciation expense of $83,250 for the nine months ended September 30, 2015 and 2014, respectively.

12

SMI X-ray Machine Capital Lease:

On July 03, 2014, Company has entered into a capital lease agreement to lease the x-ray machine that was delivered and installed in July 2014. Under the terms of the lease, the Company’s subsidiary, SMI, is to make monthly payments of $1,495, plus applicable sales tax, over a period of 60 months. At the end of the lease, SMI will have the option to purchase the MRI machines for a total purchase price of $1.00. The lease was accounted for as a capital lease for a total value of $78,250.

The gross amount of the x-ray machine held under the capital lease is $78,250 ($58,688 net book value after accumulated amortization of $19,562) at September 30, 2015.

Amortization of the capital lease assets is included in the depreciation expense of $3,913 for the three months ended September 30, 2015 and 2014, respectively.  Amortization of the capital lease assets is included in the depreciation expense of $11,738, and $3,913 for the nine months ended September 30, 2015 and 2014, respectively.

SMI PACS/RIS System Capital Lease:

On August 19, 2014, the Company has entered into a capital lease agreement to lease PACS/RIS system that was delivered and installed in December 2014. Under the terms of the lease, the Company’s subsidiary, SMI, is to make monthly payments of $3,115, plus applicable sales tax, over a period of 60 months. At the end of the lease, SMI will have the option to purchase the system for a total purchase price of $1.00. The lease was accounted for as a capital lease for a total value of $162,333.

The gross amount of the PACS/RIS system held under the capital lease is $162,333 ($116,133 net book value after accumulated amortization of $46,200) at September 30, 2015.

Amortization of the capital lease assets is included in the depreciation expense of $8,117, and $4,058 for the three months ended September 30, 2015, and 2014, respectively.  Amortization of the capital lease assets is included in the depreciation expense of $24,350, and $4,058 for the nine months ended September 30, 2015, and 2014, respectively.

PV, PN, PC PACS/RIS Capital Lease:

On November 26, 2014, the Company has entered into a capital lease agreement to lease PACS/RIS system that was delivered and installed in December 2014. Under the terms of the lease, the Company’s subsidiary, PIV, is to make monthly payments of $3,094, plus applicable sales tax, over a period of 60 months. At the end of the lease, PIV will have the option to purchase the system for a total purchase price of $1.00. The lease was accounted for as a capital lease for a total value of $167,107.

The gross amount of the PACS/RIS system held under the capital lease is $167,107 ($140,648 net book value after accumulated amortization of $26,459) at September 30, 2015.

Amortization of the capital lease assets is included in the depreciation expense of $8,355, and $0 for the three months ended September 30, 2015, and 2014, respectively.  Amortization of the capital lease assets is included in the depreciation expense of $25,065, and $0 for the nine months ended September 30, 2015, and 2014, respectively.

PV, PN, PC Computers Capital Lease:

On December 10, 2014, the Company has entered into a capital lease agreement to lease computers that were delivered and installed in December 2014. Under the terms of the lease, the Company is to make monthly payments of $813.16, plus applicable sales tax, over a period of 36 months. At the end of the lease, the company will have the option to purchase the computers for a total purchase price of $1.00. The lease was accounted for as a capital lease for a total value of $25,108.

The gross amount of the computers held under the capital lease is $25,108 ($20,575 net book value after accumulated amortization of $6,625) at September 30, 2015.

Amortization of the capital lease assets is included in the depreciation expense of $2,092, and $0 for the three months ended September 30, 2015, and 2014, respectively.  Amortization of the capital lease assets is included in the depreciation expense of $6,277, and $0 for the nine months ended September 30, 2015, and 2014, respectively.

13

CTS Computers Lease

On January 21, 2015, the Company has entered into a capital lease agreement to lease computers that were installed on the same date of acceptance. Under the terms of the lease, the company is to make monthly payments of $546, plus applicable sales tax, over a period of 36 months. At the end of the lease, the company will have the option to purchase the computers for a total purchase price of $1.00. The lease was accounted for as a capital lease for a total value of $18,997 (amount is carried in Canadian dollar).

The gross amount of the computers held under the capital lease is $18,997 ($14,776 net book value after accumulated amortization of $4,221) at September 30, 2015.

Amortization of the capital lease assets is included in the depreciation expense of $1,683, and $0 for the three months ended September 30, 2015, and 2014, respectively.  Amortization of the capital lease assets is included in the depreciation expense of $4,488, and $0 for the nine months ended September 30, 2015, and 2014, respectively.

Minimum future lease payments under the capital leases as of September 30, 2015 are as follow:

Minimum Lease Payments	Total		SMI MRI	SMI PACS/RIS Lease	SMI Xray Lease	PV,PN, PC PACS/RIS Lease	PV,PN,PC Computers Lease	CTS Computers Lease
2015	$	60,255	33,038	9,345	4,486	9,308	2,439	1,639
2016		240,916	132,152	37,380	17,944	37,128	9,758	6,554
2017		107,951	-	37,380	17,944	37,128	8,945	6,554
2018		93,545	-	37,380	17,944	37,128	-	1,092
2019		83,356	-	34,265	11,963	37,128	-	-
2020		3,094	-	-	-	3,094	-	-
Total minimum lease payments		589,118	165,190	155,750	70,282	160,914	21,142	15,840
Less amount representing interest		53,342	11,027	17,377	8,168	14,082	2,250	437
Present value of minimum lease payments		535,776	154,163	138,373	62,114	146,832	18,892	15,403
Less current portion of minimum lease payments		212,427	121,695	30,288	14,432	31,541	8,199	6,272
Long-term capital lease obligations	$	323,349	32,468	108,085	47,682	115,291	10,693	9,131

Note 9. Convertible Notes

Series B:

On December 3, 2012, the Company sold, through a private placement to accredited investors, three year 12% convertible notes (“Series B Notes”) in the aggregate principal amount of $1,865,000. On March 27, 2013, the Company sold an additional $150,000 of Series B Notes.

Series B Notes pay interest at a rate of 12% per annum, payable to the holder at 1% per month. The Notes are convertible into common shares of the Company at $0.10 per share. In addition, each holder of Series B Notes received shares dependent on the dollar amount of Notes purchased. The total number of shares issued was 5,315,000 shares of common stock of the Company. $1,865,000 of Series B Notes issued on December 3, 2012 mature on July 1, 2018; and $150,000 of Series B Notes issued March 27, 2013 mature on March 31, 2016.

For the nine months ended September 30, 2015, $181,350 of accrued interest was recorded on the notes and paid.

In accordance with ASC 470, Debt with conversion and other options, on issuance of the shares given, the Company recognized additional paid-in capital and a discount against the notes for a total of $244,275.  Amortization of the discount for the nine months ended September 30, 2015 was $61,068.

14

The Details of Series B Notes are as follows:

Issuance	December 31,		December 31,		Nine Months		Nine Months		Nine Months		September 30,		Maturity
Date	2014		2014		Ended		Ended		Ended		2015		Date
	Balance		Unamortized		September 30,		September 30,		September 30,		Balance, net
			Discount		2015		2015		2015
			Beginning		Interest		(Payments)		Amortization
			Balance		Accrued				of Debt
									Discount
03-Dec-12	$	25,000	$	(344)	$	2,250	$	(2,250)	$	281	$	24,937	31-Dec-15
03-Dec-12		125,000		(5,594)		11,250		(11,250)		3,731		123,137	31-Dec-15
03-Dec-12		50,000		(1,031)		4,500		(4,500)		844		49,813	31-Dec-15
03-Dec-12		25,000		(344)		2,250		(2,250)		281		24,937	31-Dec-15
03-Dec-12		25,000		(344)		2,250		(2,250)		281		24,937	31-Dec-15
03-Dec-12		25,000		(344)		2,250		(2,250)		281		24,937	31-Dec-15
03-Dec-12		1,500,000		(61,875)		135,000		(135,000)		50,625		1,488,750	01-Jul-18
03-Dec-12		50,000		(1,031)		4,500		(4,500)		844		49,813	31-Dec-15
03-Dec-12		15,000		(206)		1,350		(1,350)		169		14,963	31-Dec-15
03-Dec-12		100,000		(3,656)		9,000		(9,000)		2,569		98,913	31-Dec-15
27-Mar-13		25,000		(646)		2,250		(2,250)		388		24,742	31-Mar-16
27-Mar-13		25,000		(646)		2,250		(2,250)		388		24,742	31-Mar-16
27-Mar-13		25,000		(646)		2,250		(2,250)		388		24,742	31-Mar-16
Total	$	2,015,000	$	(76,706)	$	181,350	$	(181,350)	$	61,068	$	1,999,362

Following are maturities of the long –term debt in Series B Notes:

	Principal Payments		Interest Payments		Amortization of Discount
2015	$	365,000	$	60,450	$	14,088
2016		150,000		184,500		1,550
2017		-		180,000		-
2018		1,500,000		90,000
Total	$	2,015,000	$	514,950	$	15,638

Series C:

On May 22, 2014, the Company sold, through private placement to accredited investors, three year 12% convertible notes (“Series C Notes”) in the aggregate principal amount of $95,000.

The Notes bear interest at a rate of 12% per annum, payable to the holder at1% per month, with the principal amount due on May 31, 2017. The Notes are convertible into shares of the Company’s common stock at an initial conversion rate of $0.15 per share. In addition, each holder of Series C Notes received shares dependent on the dollar amount of Notes purchased. On August 25, 2014, October 31, 2014 and February 17, 2015, the Company sold an additional $75,000, $50,000 and $20,000, respectively of “series C notes”.

The total number of shares issued was 240,000 shares of common stock of the Company.

In accordance with ASC 470 on issuance of the shares given, the Company recognized additional paid-in capital and a discount against the notes for a total of $12,695. Amortization of the discount for the nine months ended September 30, 2015 was $3,772.

For the nine months ended September 30, 2015, $21,200 in accrued interest was recorded on the notes and paid.

Issuance	December 31,		Unamortized		Nine Months		Nine Months		Nine Months		Nine Months		September 30,		Maturity
Date	2014		Discount		Ended		Ended		Ended		Ended		2015		Date
	Balance		Beginning		September 30,		September 30,		September 30,		September 30,		Balance, net
			Balance		2015		2015		2015		2015
					Proceeds		Interest		(Payments)		Amortization
							Accrued				of Debt
											Discount
22-May-14	$	50,000	$	(2,417)	$	-	$	4,500	$	(4,500)	$	750	$	48,333	31-May-17
22-May-14		22,500		(1,088)		-		2,025		(2,025)		338		21,750	31-May-17
22-May-14		22,500		(1,088)		-		2,025		(2,025)		338		21,750	31-May-17
25-Aug-14		50,000		(3,419)		-		4,500		(4,500)		993		47,574	31-October-17
25-Aug-14		25,000		(1,709)		-		2,250		(2,250)		496		23,787	31-October-17
31-Oct-14		50,000		(2,479)		-		4,500		(4,500)		656		48,177	31-October-17
17-Feb-15		-		(1,040)		20,000		1,400		(1,400)		202		19,162	17-February-18
Total	$	220,000	$	(13,240)	$	20,000	$	21,200	$	(21,200)	$	3,772	$	230,532

15

Following are maturities of the long –term debt in Series C Notes:

	Principal Payments		Interest Payments		Amortization of Discount
2015	$	-	$	7,200	$	1,105
2016		-		24,400		4,876
2017		220,000		12,650		3,429
2018		20,000		400		58
Total	$	240,000	$	44,650	$	9,468

Individually issued Convertible Note:

On March 26, 2014, the Company issued a $300,000 convertible note to a non-affiliate.  The note pays interest at a rate of 12% per annum, payable to the holder at 1% per month. In addition to interest payments the Company will be making monthly payments of $5,000 towards the principal balance beginning June 1, 2014 for three years until the note due date of February 27, 2017. The note is convertible into common shares of the Company at $0.15 per share. In addition, the non-affiliate will receive 300,000 shares as part of the note agreement.

For the nine months ended September 30, 2015, $21,533 of accrued interest was recorded on the notes and paid.

In accordance with ASC 470 on issuance of the shares given, the Company recognized additional paid-in capital and a discount against the notes for a total of $25,500. Amortization of the discount for the nine months ended September 30, 2015 was $6,375.

Summary of the note is as follows:

	September 30, 2015		December 31, 2014
Convertible note Beginning Balance	$	260,000	$	300,000
Less: unamortized debt discount		(12,750)		(19,125)
Convertible notes principal, net		247,250		280,875
Less: Payments in Period		(66,533)		(66,504)
Added: Accrued interest		21,533		26,504
Total Convertible note, net	$	202,250	$	240,875
Less: short term portion, net		56,442		54,263
Long term portion, net	$	145,808	$	186,612

Following are maturity of the individually issued convertible note for each of the next 5 years:

	Principal Payments		Interest Payments		Amortization of Discount
2015	$	15,000	$	6,352	$	2,125
2016		60,000		20,748		8,500
2017		140,000		2,625		2,125
Total	$	215,000	$	29,725	$	12,750

Note 10. Promissory Notes

In June 2014, $64,937 of the SMI acquisition liability that was due as part of SMI acquisition was assigned to a promissory note accruing interest at an annual rate of 12%, and due on February 1, 2015. Interest accrued is to be paid out monthly with the principal amount due on maturity. The note has been fully paid in February 2015.

In December 2014, the Company issued a short term loan payable to a non-related party for $50,000 in proceeds. The note is due on demand and does not accrue interest. For the nine months ended September 30, 2015, the Company made payments of $54,000 towards the balance and has received additional proceeds of $4,000. As of September 30, 2015, the loan is paid out in full.

For the nine months ended September 30, 2015, the Company has issued loans total of $720,000, the loans terms call for weekly payments of $28,000 towards the principal balance and interest. The final payment was due August 18, 2015.

For the nine months ended September 30, 2015, the Company issues loans total of $429,000, the loans call for weekly payments of $13,000 towards the principal balance and interest. The final payment is due April 5, 2016.

16

In June 2015, the Company has issued a loan of $120,700, the loan terms call for a daily payment of $453, towards the principal balance and interest. The final payment is due July 7, 2016.

In June 2015 the company has issued a loan of $163,362, the loan terms call for a daily payment of $613, towards the principal balance and interest. The final payment is due July 7, 2016. Amounts are carried in Canadian Dollars.

A summary of the promissory notes is as follows:

Promissory notes at January 1, 2014	$	45,015
Added: Note assigned through December 31, 2014		64,937
Added: Accrued Interest through December 31, 2014		6,069
Added: Proceeds through December 31, 2014		50,000
Less: Payments through December 31, 2014		(31,022)
Promissory notes at December 31, 2014	$	134,999
Added: Accrued Interest through September 30, 2015		2,000
Added: Proceeds through September 30, 2015		1,425,835
Less: Payments through September 30, 2015		(1,004,973)
Added: Discount through September 30, 2015		(129,917)
Promissory notes at September 30, 2015	$	427,944
Less: Short term portion		427,944
Long term portion September 30, 2015	$	-

Note 11. Royalty Financing

On October 31, 2014, the Company entered into a royalty purchase agreement with Grenville Strategic Royalty Corp. for the amount of $2,000,000. The agreement calls for a monthly payment to the seller based on a percentage of the total of certain revenue items and subject to a minimum payment amount. For the nine months ended September 30, 2015, the Company paid a total of $346,378 in royalty payments. The amount financed is recorded net of discount to be amortized of the term. As of September 30, 2015 the Company has recorded discount amortization expense of $307,056. The balance as shown on the consolidated balance sheet as of September 30, 2015 is $1,960,679.

Note 12. Major Customers

For the nine months ending September 30, 2015 and 2014, revenue was derived primarily from radiology services.

Major customers representing more than 10% of total revenue for the nine months ended September 30, 2015 and 2014 are as follow:

	Nine Months Ended			Nine Months Ended
	September 30, 2015			September 30, 2014
Customers	Revenue amount		Revenue percentage	Revenue amount		Revenue percentage
Contract A	$	-	0%	$	650,079	17%
Contract E		436,666	12%		698,618	18%
Contract F		262,019	7%		430,57	11%

There were no closing balances for accounts receivable greater than 10% of total balance.

Note 13. Major Vendors

There were no major vendors for the nine months ended September 30, 2015.

Note 14. Related Party Transactions

During January 2015, the Company entered into an agreement with a company that is owned and controlled by a major shareholder, to provide consulting services. Fees payable for performance of the consulting services are $10,000 per month. In addition to the monthly fees, the consultant was paid at signing of the agreement, four million two hundred thousand (4,200,000) options to purchase common stock of the client at an exercise price of $0.15 per share with an expiry date of December 31, 2019; details of the options recognition is disclosed in Note 15. Fees paid to the related party consultant are included as an expense in Legal and Professional fees in the accompanying statement of operations for the period. At September 30, 2015, the Company had $0 balance owing for services rendered.

17

Note 15. Common Stock Transactions

On January 27, 2015, the Company granted options as considerations for services provided by the CEO of the company. The options are to purchase up to 4,200,000 shares of common stock, with an exercise price equal to $0.15 per share. The options shall have a five (5) year term. Inputs used in Binomial Option Pricing model were as follow: stock price at grant date: $0.0517, exercise price $0.15, expected life of the option two and a half (2.5) years, volatility of 70%, and risk free rate of 0.03%. The options were recorded on the grant date at a value of $34,683.

On January 27, 2015, the Company granted options as considerations for consulting services provided to the company. The options are to purchase up to 4,200,000 shares of common stock, with an exercise price equal to $0.15 per share. The options shall have a five (5) year term. Inputs used in Binomial Option Pricing model were as follow: stock price at grant date: $0.0517, exercise price $0.15, expected life of the option two and a half (2.5) years, volatility of 70%, and risk free rate of 0.03%. The options were recorded on the grant date at a value of $34,683.

On January 27, 2015, the Company granted options as considerations for services provided by the CFO of the Company. The options are to purchase up to 1,600,000 shares of common stock, with an exercise price equal to $0.15 per share. The options shall have a five (5) year term. Inputs used in Binomial Option Pricing model were as follow: stock price at grant date: $0.0517, exercise price $0.15, expected life of the option two and a half (2.5) years, volatility of 70%, and risk free rate of 0.03%. The options were recorded on the grant date at a value of $13,213.

For the nine months ended September 30, 2015, 200,000 shares were issued for services valued at $10,340 based upon the closing price of the Company’s common stock at the grant date.

For the nine months ended September 30, 2015, 20,000 shares were issued as part of series C convertible note agreements. The shares were valued at $1,040 based upon the closing price of the Company’s common stock at the grant date.

For the year ended December 31, 2014, 5,000 shares were issued for services valued at $150 based upon the closing price of the Company’s common stock at the grant date.

For the year ended December 31, 2014, 300,000 shares were issued as part of individually issued convertible note agreements. The shares were valued at $25,500 based upon the closing price of the Company’s common stock at the grant date.

For the year ended December 31, 2014, 220,000 shares were issued as part of series C convertible note agreements. The shares were valued at $14,280 based upon the closing price of the Company’s common stock at the grant date.

Note 16. Income Tax

The Company follows ASC 740, Income Taxes (“ASC 740”), which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between consolidated financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.

The provisions of ASC 740 require companies to recognize in their financial statements the impact of a tax position if that position is more likely than not to be sustained upon audit, based upon the technical merits of the position. ASC 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken on a tax return. ASC 740 also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods and disclosure.

Management does not believe that the Company has any material uncertain tax positions requiring recognition or measurement in accordance with the provisions of ASC 740. Accordingly, the adoption of these provisions of ASC 740 did not have a material effect on the Company’s financial statements. The Company’s policy is to record interest and penalties on uncertain tax positions, if any, as income tax expense.

Note. 17. Going Concern

As shown in the accompanying consolidated financial statements, the Company incurred net loss of $926,372 for the nine months ended September 30, 2015 as well as a working capital deficit of $1,401,076. These conditions raise substantial doubt as to the Company’s ability to continue as a going concern. Management plans to raise additional financing in order to continue its operations and fulfill its debt obligations in 2015, but there can be no assurances that the plan will be successful. These consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

18

Note 18. Subsequent events

Subsequent to quarter end, a non-related party holder of $1,500,000 of series B convertible has agreed to extend the maturity date to July 1, 2017. As consideration for this extension, the company will issue to the holder a warrant to purchase 1,500,000 shares of common stock of the company at an exercise price of $0.07 per share, which warrant will be exercisable from November 16, 2015 to and including July 1, 2018.

The Company evaluated subsequent events through the date the consolidated financial statements were issued.

19

Item 2.   MANAGEMENT’S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

Forward Looking Statements

This Form 10-Q quarterly report of Medical Imaging Corp. (the “Company”) for the three and nine months ended September 30, 2015, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby.  To the extent that there are statements that are not recitations of historical fact, such statements constitute forward-looking statements that, by definition, involve risks and uncertainties.  In any forward-looking statement, where the Company expresses an expectation or belief as to future results or events, such expectation or belief is expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the statement of expectation or belief will be achieved or accomplished.

The following are factors that could cause actual results or events to differ materially from those anticipated, and include, but are not limited to: variations in revenue; possible inability to attract investors for its equity securities or otherwise raise adequate funds from any source should the Company seek to do so; increased governmental regulation; increased competition; unfavorable outcomes to litigation involving the Company or to which the Company may become a party in the future; and a very competitive and rapidly changing operating environment.

Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof.  The Company believes the information contained in this Form 10-Q to be accurate as of the date hereof. Changes may occur after that date, and the Company will not update that information except as required by law in the normal course of its public disclosure practices.

Additionally, the following discussion regarding the Company’s financial condition and results of operations should be read in conjunction with the financial statements and related notes contained in Item 1 of Part 1 of this Form 10-Q, as well as the financial statements in Item 8 of Part II of the Company’s Form 10-K for the fiscal year ended December 31, 2014.

Business description

Medical Imaging Corp. (“MIC”), is a U.S.-based healthcare services company with a specific focus on medical diagnostic imaging.  We currently own and operate five wholly-owned subsidiaries: Canadian Teleradiology Services, Inc., which operates as Custom Teleradiology Services; Schuylkill Open MRI., which operates as Schuylkill Medical Imaging.; Partners Imaging Center of Venice, LLC; Partners Imaging Center of Naples, LLC; and Partners Imaging Center of Charlotte, LLC. With operations in the U.S. and Canada, our Company is executing a growth strategy centered on acquiring and operating profitable medical diagnostic imaging facilities and imaging services businesses with a goal of profitably increasing revenues.

MIC’s mission is to provide quality medical diagnostic imaging services to its patients across North America, delivering convenience, accuracy and the highest standards of care and service.  Our Company’s mandate is to make available, on a timely basis, valued-based on-site and remote medical imaging services for patients, hospitals, workers compensation boards and insurance companies.

Custom Teleradiology Services, Inc. (CTS)

·

Founded in 2004 and acquired by MIC in 2009, CTS is one of Canada’s leading providers of remote reading and reporting of medical diagnostic imaging scans, otherwise known as Teleradiology, for rural hospitals and clinics. Our network of board certified radiologists is, collectively providing medical imaging interpretations for our clients, helping to speed diagnoses, improve outcomes and enhance patient care.

·

On a 24/7/365 basis, CTS receives diagnostic imaging scans from hospitals, clinics and referring physicians, and transmits them to qualified radiologists, who are typically located in large urban medical centers. The receiving radiologist reads and interprets the diagnostic images and associated clinical data and prepares medical reports on the findings, which are in turn transmitted to the client allowing the hospital to continue with patient care.

·

CTS specializes in reading Magnetic Resonance Imaging (MRI), Computed Tomography (CT), Positron Emission Tomography (PET), Ultrasound (US), Nuclear Medicine (NM), Digital Mammography (MAMMO), X-Ray and Bone Mineral Densitometry (BDM) modalities.

20

·

CTS uses a leading brand Picture Archiving and Communications System (PACS) to ensure high resolution images can be delivered for interpretation in a quick, secure and highly dependable manner.  CTS also works with our IT Company to ensure our doctors workstations and hospital servers are always running.

·

Guided by the Canada Health Act of 1984, healthcare in Canada is delivered through a publicly funded healthcare system, which is mostly free at the point of use and has most services provided by private entities.  CTS’ revenues are derived from service agreements we enter with hospitals, clinics and other medical facilities where patients are treated.  Fees for services provided by CTS are billed to the government by each CTS client, which, upon being paid by the government, remits payment to CTS in accordance with the contracted payment terms.

·

CTS primary growth objectives are concentrated on optimizing our current contract portfolio and increasing our share of the Teleradiology market in the province of Ontario, expanding our geographic service region to include penetrating other Canadian provinces, and scaling our Canadian network of board certified radiologists to ensure effective support of our geographic expansion initiatives.

Schuylkill Medical Imaging (SMI)

Incorporated in 2003, SMI is the premier medical imaging facility serving patients in Schuylkill County, Pennsylvania.  SMI has provided high quality medical diagnostic imaging services for more than 12 years in a caring, safe and convenient environment.  Located in Pottsville, Pennsylvania and accredited by the American College of Radiology, SMI has the first and only Open MRI in Schuylkill County and has earned a strong reputation within the communities it serves through its board certified radiologists, highly trained technologists, medical equipment and advanced technology matched with exceptional care and service.

Our care facility currently houses two types of MRI systems – both of which provide exceptional anatomic detail and are particularly useful for diagnostic tests and procedures requiring high resolution.  Our digital imaging equipment includes a Siemens Concerto Open MRI System, as well as a closed 1.5 T Siemens Symphony MRI System.  The open MRI system is open on three sides, providing a panoramic 270° view – ideal for pediatric patients and those who may suffer from claustrophobia or are large bodied.  Our highly skilled radiologists weigh all factors to choose the right system for each individual patient to ensure the best outcome.  SMI is capable of facilitating MRI procedures that include cranial, spinal, abdominal, pelvic, musculoskeletal and head/neck scans.

·

In July 2014, SMI purchased a Viztek Digital Direct Radiography Straight Arm x-ray and a 16 slice Toshiba Aquillion Computed Tomography (CT) imaging equipment.

·

SMI’s business is highly reliant upon referrals from area physicians and group practices and does not maintain dedicated or contractual relationships with hospitals or clinics.   In fact, hospitals and clinics may compete with SMI to provide services to patients.  We believe that our community presence assists referring physicians with further enhancing their practices by providing well-coordinated and responsive care to their patients who require diagnostic imaging services; therefore we maintain an active outreach program, ensuring that the SMI brand and quality service offerings are well represented and communicated to practicing physicians in the region and to local healthcare consumers who exercise their own personal discretion in determining at what local medical imaging facility they choose to have their imaging procedures performed.

SMI prides itself on its patient-centered culture and inviting, peaceful, healing environment that is aesthetically pleasing and designed specifically to allay patient fear, anxiety and discomfort.

SMI has a staff of approximately 11 employees including a center manager responsible for all the day operations and medical manager who oversees contrast studies and can advise on patient care.

Florida Operations (PIV, PIN, PIC)

MIC owns three diagnostic centers in the State of Florida, operating under the names of Partners Imaging Center of Venice, LLC, Partners Imaging Center of Charlotte, LLC, and Partners Imaging Center of Naples, LLC.  These centers have been operating under the Partners name for more than five years and have been in their respective locations from 8 to 15 years. The centers rely on referring physicians and marketing efforts to drive business.  The centers offer a 1.5T MRI and 16 slice CT in Naples, a 1.5T MRI in Charlotte, and 3T MRI, 16 slice CT, ultrasound, PET and X-ray at the Venice location. Reports are provided to the patients’ physician within 24 hours and as quick as 60 minute for emergency exams.

Combined, the Florida operations have approximately 18 employees, including center managers.  Radiology reads are provided by a third party radiology consulting group.

21

Canadian Government Regulation

Our CTS subsidiary is subject to extensive regulation by the Canadian federal government, as well as the governments of the provinces and territories in which we conduct our business. A diagnostic imaging clinic or hospital must be licensed by the Ministry of Health and sanctioned by the College of Physicians and Surgeons in the province in which it is located.

In addition to extensive existing Canadian government healthcare regulation, there could be at the federal and provincial levels reforms affecting the payment for and availability of diagnostic healthcare services. Limitations on reimbursement amounts and other cost containment pressures could result in a decrease in the revenue we expect to receive for each scan we perform. It is not clear at this time what proposals, if any, will be adopted or, if adopted, what affect these proposals would have on our business.

U.S. Government Regulation

Our US subsidiaries are subject to extensive regulation under federal, State, and local laws.  This includes, but is not limited to complying with HIPPA, Accreditation standards, Medicare and private insurance standards. In addition, we believe that our business will continue to be subject to increasing regulation, the scope and effect of which we cannot predict.

Competition

We compete with numerous public and private diagnostic imaging clinics. We also compete for the hiring of qualified medical experts and MRI, CT and x-ray technicians to perform and evaluate the diagnostic imaging scans.  Most of our current competitors have, and our future competitors are expected to have, greater resources than us. Therefore, our ability to compete largely depends on our financial resources and capacity.

Customers

Between direct hospital contracts and satellite hospitals that feed into the main hospital, we have a client roster of more than 18 hospitals that rely on CTS. The loss of any of these clients would have a negative impact on the Company.

The diagnostic imaging centers rely on a referral base of specialized and family practitioners in each respective community. The average center may have over 100 local physicians that refer patients to us for medical imaging services.  In addition, each center uses marketing efforts and community involvement to reach out and educate patients that they have a choice as to where to have a scan.

For our Florida centers we have a sizeable amount of selfpay patients in the winter time from foreign visitors.

Employees

MIC currently has one full time executive (Chief Executive Officer), one part time executive (Chief Financial Officer) and 40 employees who include accounting staff, administrators, as well as technical employees and imaging center location managers. In addition, the Company employs as many as 40 sub-contractors who are physicians, radiologists, accountants, business development consultants, clerical staff and IT professionals.

Operations

CTS

During the third quarter, CTS was focusing on client relations, and business opportunities to add new clients.

SMI

In the third quarter, efforts were directed to continually increase patient scans across all modalities.  Volume was strong with year over year increases.  Marketing efforts continue to focus on referring physician satisfaction, patient experience at the clinic, quality read reporting and community involvement.

PIV, PIN, PIC, (Florida)

The third quarter was consistent with the prior year’s scan volume.  The Company continued to work on the necessary permitting required to process billings for medical scans and readings. Licensing was granted subsequent to quarter end in October 2015 and the company is now able to process billings in house which will eliminate billing services fees, as well as contract radiologists at better reading fees rates. The third quarter is considered the softest for Florida due to less tourists, snowbirds, and vacation by local residents.

22

Each center paid specific attention to marketing efforts and patient satisfaction.

Overall Operating Results:

For the three months ended September 30, 2015, revenues from medical scans services were $1,162,210 compared to $594,664 for the three months ended September 30, 2014, an increase of 95% or $567,546. The increase in revenue was owing to the additional revenue of PIV, PIN, and PIC, as well as an increase in scan volume for SMI.

For the three months ended September 30, 2015 revenues from teleradiology services was $513,189 compared to $680,677 for the three months ended September 30, 2014, a decrease of 25% or $167,488. The decrease in revenue from teleradiology services of 25% is related to revenues carried in Canadian dollar and a client which stopped service mid 2014. The exchange rate used to convert CTS revenues carried in Canadian dollars for the three months ended September 30, 2014 was 0.9216, while the exchange rate used to convert CTS revenue carried in Canadian dollars for the three months ended September 30, 2015 was 0.7557, a difference of 22%. The remaining 3% decrease in revenue was due to a loss of a major customer in August 2014.

For the three months ended September 30, 2015, cost of sales relating to radiology services were $937,795 compared to $711,346 for the three months ended September 30, 2014, an increase of 32% or $226,449. The increase in cost of sales was due to the overall increase in revenues, as well as the company change in allocating medical imaging technicians wages as part of cost of services starting in the first quarter of 2015.

Operating expenses for the three months ended September 30, 2015 and, September 30, 2014, totalled $880,060 and $473,562, respectively.

During the three months ended September 30, 2015, we incurred $137,116 in depreciation expenses, $82,985 in legal and professional fees, $172,640 in general and administrative costs, $5,100 in management fees, $5,833 in advertising and promotion, $318,167 for labor, and $148,977 for rent and insurance.

During the three months ended September 30, 2014, we incurred $50,252 in amortization expense, $40,322 in legal and professional fees, $94,332 in general and administrative costs, $4,778 in management fees, $8,290 in advertising and promotion, $221,148 for labor, and $50,258 for rent and insurance.

For the nine months ended September 30, 2015, revenues from medical scans services were $3,921,450 compared to $1,555,083 for the nine months ended September 30, 2014, an increase of 152 % or $2,366,367. The increase in revenue was owing to the additional revenue of PIV, PIN, and PIC as well as an increase in scan volume for SMI.

For the nine months ended September 30, 2015 revenues from teleradiology services was $1,578,767 compared to $2,232,320 for the nine months ended September 30, 2014, a decrease of 29 % or $653,553. The decrease in revenue from teleradiology services of 29% is related to revenues carried in Canadian dollar. The exchange rate used to convert CTS revenues carried in Canadian dollars for the nine months ended September 30, 2015 was 0.7937, while the exchange rate used to convert CTS revenue carried in Canadian dollars for the nine months ended September 30, 2014 was 0.9184, a difference of about 16%. The remaining 14% decrease in revenue was due to a loss of a major customer in August 2014.

For the nine months ended September 30, 2015, cost of sales relating to radiology services were $2,865,499 compared to $2,212,967 for the nine months ended September 30, 2014, an increase of 29% or $652,532. The increase in cost of sales was due to the overall increase in revenues, as well as the company change in allocating medical imaging technicians wages as part of cost of services starting in the first quarter of 2015.

Operating expenses for the nine months ended September 30, 2015 and 2014, totalled $2,750,010 and $1,340,602, respectively.

During the nine months ended September 30, 2015, we incurred $409,854 in depreciation expense, $305,180 in legal and professional fees including $34,683 in consulting fees pertaining to 4,200,000 stock options issued, $525,065 in general and administrative costs, $28,513 in management fees including $13,213 in management fees pertaining to 1,600,000 stock options issued, $23,415 in advertising and promotion, $957,660 for labor including $34,683 in employee compensation pertaining to 4,200,000 stock options issued, and $463,591 for rent and insurance.

During the nine months ended September 30, 2014, we incurred $152,832 in amortization and depreciation expenses, $138,400 in legal and professional fees, $202,829 in general and administrative costs, $13,866 in management fees, $42,543 in advertising and promotion, $597,412 for labor, and $147,088 for rent and insurance.

23

High legal and professional expenses for the three and nine months ended September 30, 2015 were due to dealings with attorneys in regards to the Florida health agency required permitting. The Company estimated associated cost to total about $90,000 for the nine months ended September 30, 2015. Licensing was granted in October 2015; as such the company is expected to substantially reduce its legal expenses in future periods.

The Company expects to generate positive cash flow in 2015 in order to service its obligations but will require substantial investment in the near term in order to expand as we implement our business plan.

Liquidity and Capital Resources:

The Company has historically used a combination of financings to operate its business and fund its acquisitions and working capital from generated revenues from its ongoing operations.  The Company from time to time has sold shares of common stock and warrants and issued convertible notes.  In 2014 it raised $520,000 from the sale of convertible notes to fund the additional expansion of SMI and entered into a royalty agreement under which it raised an aggregate of $2,000,000 to fund the acquisitions of PIV, PIN, and PIC.

The Company’s operations have produced $1,675,399 and $5,500,217 of revenues for the three and nine months ended September 30, 2015, respectively, which have been used to fund its operating expenses and to reduce its liabilities. The Company expects that current operations will be able to cover its operating expenses on an ongoing basis through 2015 and beyond.

Based on the debt payment obligations of the Company that are due within the next 12 months, there is doubt about its ability to continue as a going concern, and the Company’s continued operations therefore are dependent upon either increasing revenues or adequate additional financing being raised, or both, to enable it to continue its operations as currently conducted.  Alternatively, the Company could adjust some of its operational requirements or modify some of its debt obligations; however, these changes may not necessarily provide sufficient funds to continue as a going concernIn the event that the Company is unable to continue as a going concern, it may be forced to realize upon its assets or even elect or be required to seek protection from its creditors as provided by law or be subject to claims by creditors or a general creditor action. To date, management has not considered these alternatives as a likely outcome, since it has continuing revenues from operations and is considering capital raising actions.

As of September 30, 2015, our assets totalled $6,025,464 which consisted of cash balances, accounts receivable, pre - paid expenses, deposits, intangible assets and property and equipment. As of September 30, 2015, our total liabilities consisted of accounts payable and accrued liabilities of $1,533,406, obligations under capital lease of $535,793, promissory notes of $427,944, and non-related party convertible notes of $2,432,147 (net of discount). As of September 30, 2015, we had an accumulated deficit of $2,965,968 and a working capital deficit of $1,401,076.

As of September 30, 2015, the Company had promissory notes to non–related parties for a total amount of $427,944. $10,266 of the promissory notes had scheduled monthly payments of $1,295 including interest at a rate of 6% per annum. This note is expected to mature on February 18, 2016. $265,000 of the promissory notes call for weekly payments of $13,000 towards the principal balance and interest. The final payment was due April 6, 2016. $67,541 of the notes calls for a daily payment of $465 towards the principal and interest with the last payment scheduled for July 7, 2016. $85,137 of the notes call for a daily payment of $571 towards the principal balance and interest with the last payment scheduled for July 7, 2016.

On December 5, 2012, the Company sold, through a private placement to accredited investors, three year 12% convertible notes (“Series B Notes”) in the aggregate principal amount of $1,865,000. The Notes pay interest at a rate of 12% per annum, payable to the holder at 1% per month, and $365,000 is due December 31, 2015, and $1,500,000 is due on July 1, 2018. On March 27, 2013 the Company sold an additional $150,000 of Series B Notes.  These notes have the same terms and mature on March 31, 2016. The Notes are convertible into common shares of the Company at $0.10 per share. In addition, each purchaser of the Notes received shares dependent on the dollar amount of Notes purchased. The total number of shares issued was 5,315,000 shares of common stock of the Company. A detailed schedule of the Notes is presented in Note 9 to the consolidated financial statements.

On March 26, 2014 the Company issued $300,000 in convertible note (“Individually issued note”) to a non-affiliate.  The note pays interest at a rate of 12% per annum, payable to the holder at 1% per month. In addition to interest payments, the Company will be making monthly payments of $5,000 towards the principal balance beginning June 1, 2014 for three years until the note due date of February 27, 2017. The note is convertible into common shares of the Company at $0.15 per share. In addition, the purchaser of the note received 300,000 shares as part of the note agreement.  A detailed schedule of the Note is presented in Note 9 to the consolidated financial statements.

On May 22, 2014, the Company sold, through private placement to accredited investors, three year 12% convertible notes (“Series C Notes”) in the aggregate principal amount of $95,000.

24

The Notes bear interest at a rate of 12% per annum, payable to the holder at1% per month, with the principal amount due on May 31, 2017. The Notes are convertible into shares of the Company’s common stock at an initial conversion rate of $0.15 per share. In addition, each holder of Series C Notes received shares dependent on the dollar amount of Notes purchased. The total number of shares issued was 95,000 shares of common stock of the Company. A detailed schedule of the Notes is presented in Note 9 to the consolidated financial statements. On October 31, 2014, the Company sold, through private placement to accredited investor, an additional series C note in the principal amount of $50,000, and has issued 50,000 shares of common stock of the company accordingly.

In May 2014, the Company received proceeds of $50,000 through private placement from an accredited investor, and in June 2014 the Company assigned $25,000 of the SMI acquisition liability that was due as part of SMI acquisition (see Note 4) to loans payable. The loans were held with the Company until they were registered with Pennsylvania Securities Commission and were permitted to sell to the Pennsylvania residents investors Series C convertible note. On August 25, 2014 Series C Notes were issued to the investors and 75,000 shares of common stock of the Company were issued.

On February 17, 2015 the Company sold, through private placement to accredited investor, an additional series C note in the principal amount of $20,000, and has issued 20,000 shares of common stock of the company accordingly.

The royalty financing arrangement was entered into on October 31, 2014 with Grenville Strategic Royalty Corp.  The royalty was purchased for $2,000,000 in return for a series of payments based on a percentage of certain revenue items of the Company.  The Company and the royalty holder may agree to a subsequent increase in the amount of the royalty purchase by up to an additional $1,000,000.  The royalties are payable on a monthly basis, subject to an agreed upon minimum amount.  The royalty holder may advance additional sums in which case the royalty payment percentage and minimum amounts will be adjusted. The royalty payments will extend for a period of up to 10 years, which may be shortened if, depending on the amount of the royalty purchase, the Company has paid an agreed upon aggregate royalty amount.  The Company has certain rights to buy out the royalty payments, including in the event of a change of control of the Company, which are calculated based on a variable formula at a multiple of the purchase amount and other factors.

The Company intends to explore capital raising options in the near term which may include the issuance of additional debt and the sale of equity or equity based securities.  The Company has no agreements or arrangements for additional capital at this time.  There can be no assurance that it will be able to raise additional capital, or if funds are offered, that they will on terms acceptable to the Company. A substantial amount of the assets of the Company, held through its subsidiaries, are pledged to secure certain debt; therefore, the ability of the Company to issue secured debt may be limited or require waivers or modifications to the current outstanding debt, which the current lenders do not have to provide.

Off Balance Sheet Arrangements

None.

New Accounting Pronouncements

There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s condensed consolidated financial position, results of operations or cash flows.

Item 3 – Quantitative and Qualitative Analysis of Market Risks

There are no material changes in the market risks faced by us from those reported in our Annual Report on Form 10-K for the year ended December 31, 2014.

Item 4T. – Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in the Company’s reports filed or submitted under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the Company’s reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

25

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this quarterly report, management carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this quarterly report.

Limitations on Effectiveness of Controls and Procedures

Our management, which includes our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs.  Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected.  These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.  Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.  Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Changes in Internal Controls over Financial Reporting

In connection with the evaluation of our internal controls, our principal executive officer and principal financial officer have determined that during the period covered by this quarterly report, there have been no changes to our internal controls over financial reporting that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

PART II

ITEM 1. Legal Proceedings

On December 27, 2011, Geoffrey Blackner v. Schuylkill Open MRI, et al litigation, docketed in the Schuylkill County Court of Common Pleas, No. S15802011 was commenced against SMI by Mr. and Mrs. Blackner (“Plaintiffs”). The Plaintiffs allege that a radiologist at Schuylkill Medical Center was negligent in not finding the T1-2 disc herniation when interpreting a CT scan of Mr. Blackner’s head and neck. They further allege that a second doctor was negligent in not finding the T1-2 disc herniation when interpreting an MRI of Mr. Blackner’s cervical spine. Plaintiffs allege that SMI is vicariously liable for this negligence, because the second doctor was an independent contractor of SMI. Plaintiffs’ argue that the delay in discovering the T1-2 disc herniation, and thus the delay in surgery for that disc herniation, resulted in the damages to Mr. Blackner, specifically to his right hand. Mrs. Blackner has a loss of consortium claim.  SMI has passed this case to its insurer and has received a full indemnity from the seller of SMI to MIC for this claim. The Company has fully paid its insurance deductible and does not anticipate any further monetary damages from this claim.

ITEM 1A. Risk Factors

Not Applicable

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

The Company issued 20,000 shares in February 2015 at a per share price of $0.052 to purchasers of $20,000 of a convertible note issued in February of 2015.

The Company issued 200,000 shares in January 2015 at a per share price of $0.0517 for services.

These securities were issued in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act and Regulation D thereunder.

26

ITEM 3. Defaults Upon Senior Securities

None

ITEM 4. Mine Safety Disclosures

None

ITEM 5. Other Information

None

ITEM 6. Exhibits

(a) Exhibits.

Exhibit No.	Description
31.1	Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as enacted by Section 302 of the Sarbanes-Oxley Act of 2002*
31.2	Certification of Chief Financial Officer, pursuant to Rule 13a-14(a) of the Exchange Act, as enacted by Section 302 of the Sarbanes-Oxley Act of 2002*
32.1	Certification of Chief Executive Officer and Chief Financial Officer, pursuant to 18 United States Code Section 1350, as enacted by Section 906 of the Sarbanes-Oxley Act of 2002*

* Filed herewith.

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDICAL IMAGING CORP.
By:	/s/ Mitchell Geisler
	Mitchell Geisler
	Chief Executive Officer
Date:	November 16, 2015

MEDICAL IMAGING CORP.
By:	/s/ Richard Jagodnik
	Richard Jagodnik
	Chief Financial Officer (Principal Financial Officer)
Date:	November 16, 2015

27